Terms: = Breast cancer AND ARID1B, 6A3-5, 57492, ENSG00000049618, p250R, KIAA1235, ELD/OSA1, DAN15, BRIGHT, BAF250b AND Clinical Outcome
3 results:
1. Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified breast Carcinomas.
Luhtala S; Haapaniemi T; Staff S; Isola J
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):175-186. PubMed ID: 30358612
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Marouf C; Göhler S; Filho MI; Hajji O; Hemminki K; Nadifi S; Försti A
BMC Cancer; 2016 Feb; 16():165. PubMed ID: 26920143
[TBL] [Abstract] [Full Text] [Related]
3. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients.
Perez SA; Karamouzis MV; Skarlos DV; Ardavanis A; Sotiriadou NN; Iliopoulou EG; Salagianni ML; Orphanos G; Baxevanis CN; Rigatos G; Papamichail M
Clin Cancer Res; 2007 May; 13(9):2714-21. PubMed ID: 17473204
[TBL] [Abstract] [Full Text] [Related]
